Cart
sales@molnova.com
CPX-351
CAS No. 1256639-86-7
CPX-351( —— )
Catalog No. M34561 CAS No. 1256639-86-7
CPX-351 (Vyxeos) is a liposomal encapsulant of cytarabine and Zoerythromycin with potential antitumor activity and can be used in the study of acute myeloid leukemia.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 2423 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameCPX-351
-
NoteResearch use only, not for human use.
-
Brief DescriptionCPX-351 (Vyxeos) is a liposomal encapsulant of cytarabine and Zoerythromycin with potential antitumor activity and can be used in the study of acute myeloid leukemia.
-
DescriptionCPX-351 (Vyxeos) is a liposomal encapsulant of cytarabine and Zoerythromycin with potential antitumor activity and can be used in the study of acute myeloid leukemia.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorOthers
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1256639-86-7
-
Formula Weight770.74
-
Molecular FormulaC36H42N4O15
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESO[C@@H]1[C@@H](O[C@H](CO)[C@H]1O)N2C(=O)N=C(N)C=C2.OC=1C2=C([C@@H](O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C[C@@](C(C)=O)(O)C2)C(O)=C4C1C(=O)C=5C(C4=O)=C(OC)C=CC5
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog
related products
-
Paliroden
Paliroden is a non-peptide compound that can be taken orally and is used for supplementing neuro-nutrition. It stimulates the synthesis of endogenous neurotrophic factors and is employed in the research of neurodegenerative diseases such as Alzheimer's and Parkinson's.
-
W-5 hydrochloride
calmodulin antagonist.
-
Glaucine
Glaucine has antitussive antioxidative potential and antiviral activities it may be an anti-arthritic agent it can enhance LPS and zymosan-induced IL-10 production. Glaucine can inhibit the migration and invasion of human breast cancer cells by MMP-9 inhibitory activity attenuating IκBα and NF-κB activities.
